Chinese Journal of Antituberculosis ›› 2026, Vol. 48 ›› Issue (4): 468-476.doi: 10.19982/j.issn.1000-6621.20250444
• Original Articles • Previous Articles Next Articles
Wang Yongbing1, Zhong Yuexiang2, Fu Xiuying3, Zhang Ying1, Weng Wenpei4, Zhou Fangjing4, Yang Yingzhou5, Luo Jilun2(
)
Received:2025-11-12
Online:2026-04-10
Published:2026-04-02
Contact:
Luo Jilun,Email:41352035@qq.com
Supported by:CLC Number:
Wang Yongbing, Zhong Yuexiang, Fu Xiuying, Zhang Ying, Weng Wenpei, Zhou Fangjing, Yang Yingzhou, Luo Jilun. Survey of Mycobacterium tuberculosis infection rate and analysis of associated factors among three priority populations in Yingde’s zero-TB community pilot areas,Guangdong Province[J]. Chinese Journal of Antituberculosis, 2026, 48(4): 468-476. doi: 10.19982/j.issn.1000-6621.20250444
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20250444
| 特征 | 密切接触者 (856名) | 糖尿病患者 (687例) | 呼吸系统疾病 就诊者(236例) | 全部重点人群 (1743例) |
|---|---|---|---|---|
| 性别[例(构成比,%)] | ||||
| 男性 | 469(57.79) | 324(47.16) | 108(45.76) | 882(50.60) |
| 女性 | 387(45.21) | 363(52.84) | 128(54.24) | 861(49.40) |
| 年龄组[例(构成比,%)] | ||||
| <15岁 | 193(22.55) | 0(0.00) | 20(8.47) | 213(12.22) |
| 15~44岁 | 260(30.37) | 50(7.28) | 48(20.34) | 349(20.02) |
| 45~59岁 | 259(30.26) | 402(58.51) | 103(43.64) | 756(43.38) |
| 60~65岁 | 144(16.82) | 235(34.21) | 65(27.55) | 425(24.38) |
| 体质量指数[例(构成比,%)] | ||||
| <18.5kg/m2 | 179(20.91) | 18(2.62) | 32(13.56) | 224(12.85) |
| 18.5~23.9kg/m2 | 428(50.00) | 292(42.50) | 116(49.15) | 818(46.93) |
| 24~27.9kg/m2 | 188(21.96) | 273(39.74) | 66(27.97) | 519(29.78) |
| ≥28kg/m2 | 61(7.13) | 104(15.14) | 22(9.32) | 182(10.44) |
| 吸烟史[例(构成比,%)] | ||||
| 有 | 202(23.60) | 164(23.87) | 62(26.27) | 419(24.04) |
| 无 | 654(76.40) | 523(76.13) | 174(73.73) | 1324(75.96) |
| 特征 | 密切接触者 (856名) | 糖尿病患者 (687例) | 呼吸系统疾病就诊者 (236例) | 全部重点人群 (1743例) | ||||
|---|---|---|---|---|---|---|---|---|
| 接受筛查 | 未接受筛查 | 接受筛查 | 未接受筛查 | 接受筛查 | 未接受筛查 | 接受筛查 | 未接受筛查 | |
| 性别[例(构成比,%)] | ||||||||
| 男性 | 413(88.06) | 56(11.94) | 266(82.10) | 58(17.90) | 108(100.00) | 0(0.00) | 768(87.07) | 114(12.93) |
| 女性 | 344(88.89) | 43(11.11) | 304(83.75) | 59(16.25) | 125(97.66) | 3(2.34) | 756(87.80) | 105(12.20) |
| 年龄组[例(构成比,%)] | ||||||||
| <15岁 | 175(90.67) | 18(9.33) | 0(0.00) | 0(0.00) | 20(100.00) | 0(0.00) | 195(91.55) | 18(8.45) |
| 15~44岁 | 199(76.54) | 61(23.46) | 34(68.00) | 16(32.00) | 46(95.83) | 2(4.17) | 270(77.36) | 79(22.64) |
| 45~59岁 | 245(94.59) | 14(5.41) | 337(83.83) | 65(16.17) | 103(100.00) | 0(0.00) | 677(89.55) | 79(10.45) |
| 60~65岁 | 138(95.83) | 6(4.17) | 199(84.68) | 36(15.32) | 64(98.46) | 1(1.54) | 382(89.88) | 43(10.12) |
| 体质量指数[例(构成比,%)] | ||||||||
| <18.5kg/m2 | 169(94.41) | 10(5.59) | 14(77.78) | 4(22.22) | 32(100.00) | 0(0.00) | 210(93.75) | 14(6.25) |
| 18.5~23.9kg/m2 | 357(83.41) | 71(16.59) | 244(83.56) | 48(16.44) | 114(98.28) | 2(1.72) | 697(85.21) | 121(14.79) |
| 24~27.9kg/m2 | 172(91.49) | 16(8.51) | 229(83.88) | 44(16.12) | 65(98.48) | 1(1.52) | 458(88.25) | 61(11.75) |
| ≥28kg/m2 | 59(96.72) | 2(3.28) | 83(79.81) | 21(20.19) | 22(100.00) | 0(0.00) | 159(87.36) | 23(12.64) |
| 吸烟史[例(构成比,%)] | ||||||||
| 有 | 177(87.62) | 25(12.38) | 143(87.20) | 21(12.80) | 62(100.00) | 0(0.00) | 373(89.02) | 46(10.98) |
| 无 | 580(88.69) | 74(11.31) | 427(81.64) | 96(18.36) | 171(98.28) | 3(1.75) | 1151(86.93) | 173(13.07) |
| 合计 | 757(88.43) | 99(11.57) | 570(82.97) | 117(17.03) | 233(98.73) | 3(1.27) | 1524(87.44) | 219(12.56) |
| 特征 | EC检测情况 | 阳性检测结果 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 登记人数 (856名) | 筛查人数 (757名) | 筛查率 (%) | χ2值 | P值 | 阳性例数 (78例) | 感染率 (%) | χ2值 | P值 | |
| 性别[例(构成比,%)] | 0.143 | 0.706 | 0.018 | 0.894 | |||||
| 男性 | 469 | 413 | 88.06 | 42 | 10.17 | ||||
| 女性 | 387 | 344 | 88.89 | 36 | 10.47 | ||||
| 年龄组[例(构成比,%)] | 54.237 | <0.001 | 3.158 | 0.368 | |||||
| <15岁 | 193 | 175 | 90.67 | 13 | 7.43 | ||||
| 15~44岁 | 260 | 199 | 76.54 | 21 | 10.55 | ||||
| 45~59岁 | 259 | 245 | 94.59 | 31 | 12.65 | ||||
| 60~65岁 | 144 | 138 | 95.83 | 13 | 9.42 | ||||
| 体质量指数[例(构成比,%)] | 23.922 | <0.001 | 4.745 | 0.191 | |||||
| <18.5kg/m2 | 179 | 169 | 94.41 | 12 | 7.10 | ||||
| 18.5~23.9kg/m2 | 428 | 357 | 83.41 | 38 | 10.64 | ||||
| 24~27.9kg/m2 | 188 | 172 | 91.49 | 18 | 10.47 | ||||
| ≥28kg/m2 | 61 | 59 | 96.72 | 10 | 16.95 | ||||
| 吸烟史[例(构成比,%)] | 0.170 | 0.680 | 4.807 | 0.028 | |||||
| 有 | 202 | 177 | 87.62 | 26 | 14.69 | ||||
| 无 | 654 | 580 | 88.69 | 52 | 8.97 | ||||
| 指示病例情况[例(构成比,%)] | 2.355 | 0.125 | 6.910 | 0.009 | |||||
| 病原学阳性 | 492 | 428 | 86.99 | 55 | 12.85 | ||||
| 病原学阴性 | 364 | 329 | 90.38 | 23 | 6.99 | ||||
| 特征 | EC检测情况 | 阳性检测结果 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 登记人数 (687名) | 筛查人数 (570名) | 筛查率 (%) | χ2值 | P值 | 阳性例数 (48例) | 感染率 (%) | χ2值 | P值 | |
| 性别[例(构成比,%)] | 0.329 | 0.566 | 0.234 | 0.629 | |||||
| 男性 | 324 | 266 | 82.10 | 24 | 9.02 | ||||
| 女性 | 363 | 304 | 83.75 | 24 | 7.89 | ||||
| 年龄组[例(构成比,%)] | 8.627 | 0.013 | 0.390 | 0.823 | |||||
| <15岁 | 0 | 0 | 0.00 | 0 | 0.00 | ||||
| 15~44岁 | 50 | 34 | 68.00 | 2 | 5.88 | ||||
| 45~59岁 | 402 | 337 | 83.83 | 28 | 8.31 | ||||
| 60~65岁 | 235 | 199 | 84.68 | 18 | 9.05 | ||||
| 体质量指数[例(构成比,%)] | 1.313 | 0.726 | 3.842 | 0.279 | |||||
| <18.5kg/m2 | 18 | 14 | 77.78 | 2 | 14.29 | ||||
| 18.5~23.9kg/m2 | 292 | 244 | 83.56 | 15 | 6.15 | ||||
| 24~27.9kg/m2 | 273 | 229 | 83.88 | 21 | 9.17 | ||||
| ≥28kg/m2 | 104 | 83 | 79.81 | 10 | 12.05 | ||||
| 吸烟史[例(构成比,%)] | 2.722 | 0.099 | 1.059 | 0.303 | |||||
| 有 | 164 | 143 | 87.20 | 15 | 10.49 | ||||
| 无 | 523 | 427 | 81.64 | 33 | 7.73 | ||||
| 糖尿病病程[例(构成比,%)] | 0.862 | 0.353 | 0.200 | 0.655 | |||||
| <10年 | 605 | 499 | 82.48 | 43 | 8.62 | ||||
| ≥10年 | 82 | 71 | 86.59 | 5 | 7.04 | ||||
| 血糖控制情况[例(构成比,%)] | 0.010 | 0.920 | 0.065 | 0.799 | |||||
| 控制良好 | 526 | 436 | 82.89 | 36 | 8.26 | ||||
| 控制不佳 | 161 | 134 | 83.23 | 12 | 8.96 | ||||
| 特征 | EC检测情况 | 阳性检测结果 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 登记人数 (236名) | 筛查人数 (233名) | 筛查率 (%) | χ2值 | P值 | 阳性例数 (23例) | 感染率 (%) | χ2值 | P值 | |
| 性别[例(构成比,%)] | 1.036 | 0.309 | 3.652 | 0.056 | |||||
| 男性 | 108 | 108 | 100.00 | 15 | 13.89 | ||||
| 女性 | 128 | 125 | 97.66 | 8 | 6.40 | ||||
| 年龄组[例(构成比,%)] | 5.192 | 0.158 | 6.278 | 0.099 | |||||
| <15岁 | 20 | 20 | 100.00 | 0 | 0.00 | ||||
| 15~44岁 | 48 | 46 | 95.83 | 3 | 6.52 | ||||
| 45~59岁 | 103 | 103 | 100.00 | 14 | 13.59 | ||||
| 60~65岁 | 65 | 64 | 98.46 | 6 | 9.38 | ||||
| 体质量指数[例(构成比,%)] | 1.582 | 0.664 | 5.152 | 0.161 | |||||
| <18.5kg/m2 | 32 | 32 | 100.00 | 1 | 3.13 | ||||
| 18.5~23.9kg/m2 | 116 | 114 | 98.28 | 9 | 7.89 | ||||
| 24~27.9kg/m2 | 66 | 65 | 98.48 | 9 | 13.85 | ||||
| ≥28kg/m2 | 22 | 22 | 100.00 | 4 | 18.18 | ||||
| 吸烟史[例(构成比,%)] | 0.000 | 0.569 | 0.873 | 0.350 | |||||
| 有 | 62 | 62 | 100.00 | 8 | 12.90 | ||||
| 无 | 174 | 171 | 98.28 | 15 | 8.77 | ||||
| 最终诊断[例(构成比,%)] | 0.005 | 0.946 | 0.016 | 0.899 | |||||
| 肺炎 | 37 | 36 | 97.30 | 3 | 8.33 | ||||
| 其他 | 199 | 197 | 98.99 | 20 | 10.15 | ||||
| 重点人群/因素 | β值 | s | Z值 | Wald χ2值 | P值 | OR值 | 95%CI值 |
|---|---|---|---|---|---|---|---|
| 密切接触者 | |||||||
| 性别 | |||||||
| 女性 | 1.000 | ||||||
| 男性 | ―0.398 | 0.319 | ―1.246 | 1.553 | 0.213 | 0.672 | 0.359~1.256 |
| 吸烟史 | |||||||
| 无 | 1.000 | ||||||
| 有 | 0.716 | 0.359 | 1.994 | 3.977 | 0.046 | 2.047 | 1.012~4.140 |
| 年龄组 | |||||||
| <15岁 | ―0.308 | 0.385 | ―0.800 | 0.641 | 0.423 | 0.735 | 0.345~1.563 |
| 15~44岁 | 1.000 | ||||||
| 45~59岁 | 0.086 | 0.306 | 0.281 | 0.080 | 0.778 | 1.090 | 0.599~1.985 |
| 60~65岁 | ―0.233 | 0.379 | ―0.614 | 0.377 | 0.539 | 0.792 | 0.377~1.664 |
| 指示病例情况 | |||||||
| 病原学阴性 | 1.000 | ||||||
| 病原学阳性 | 0.679 | 0.263 | 2.585 | 6.682 | 0.010 | 1.972 | 1.178~3.301 |
| 糖尿病患者 | |||||||
| 性别 | |||||||
| 女性 | 1.000 | ||||||
| 男性 | 0.166 | 0.303 | 0.547 | 0.299 | 0.584 | 1.180 | 0.652~2.138 |
| 年龄组 | |||||||
| <15岁 | - | ||||||
| 15~44岁 | 1.000 | ||||||
| 45~59岁 | 0.408 | 0.758 | 0.538 | 0.289 | 0.591 | 1.503 | 0.340~6.642 |
| 60~65岁 | 0.502 | 0.773 | 0.650 | 0.422 | 0.516 | 1.652 | 0.363~7.516 |
| 呼吸系统疾病患者 | |||||||
| 性别 | |||||||
| 女性 | 1.000 | ||||||
| 男性 | 1.008 | 0.471 | 2.139 | 4.574 | 0.032 | 2.740 | 1.088~6.903 |
| 年龄组 | |||||||
| <15岁 | ―13.064 | 528.674 | ―0.025 | 0.001 | 0.980 | 0.000 | 0.000~null |
| 15~44岁 | 1.000 | ||||||
| 45~59岁 | 0.857 | 0.669 | 1.281 | 1.640 | 0.200 | 2.357 | 0.635~8.753 |
| 60~65岁 | 0.241 | 0.744 | 0.324 | 0.105 | 0.746 | 1.272 | 0.296~5.465 |
| [1] | 屈燕, 李涛, 马文斌, 等. 世界卫生组织《2025年全球结核病报告》解读. 结核与肺部疾病杂志, 2025, 6 (6): 613-623. doi:10.19983/j.issn.2096-8493.20250178. |
| [2] | Houben RM, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med, 2016, 13(10): e1002152. doi:10.1371/journal.pmed.1002152. |
| [3] | 马艳, 成诗明. 加速我国结核潜伏感染筛查与预防性治疗的建议. 实用医学杂志, 2023, 39(11): 1335-1340. doi:10.3969/j.issn.1006-5725.2023.11.003. |
| [4] | 成君, 赵雁林. 创建无结核社区终止结核病流行. 中国防痨杂志, 2021, 43(11): 1120-1124. doi:10.3969/j.issn.1000-6621.2021.11.004. |
| [5] | 陈馨仪, 任少凡, 郑纯胜. 浙江启动“无结核社区”建设. 健康报, 2023-03-30(003). doi:10.28415/n.cnki.njika.2023.001180. |
| [6] | 中国医学科学院病原生物学研究所, 中国疾病预防控制中心, 中国科学院地理科学与资源研究所. 全国结核分枝杆菌潜伏感染率估算专家共识. 中国防痨杂志, 2022, 44(1): 4-8. doi:10.19982/j.issn.1000-6621.20210662. |
| [7] | 中华人民共和国国家卫生健康委员会办公厅. 国家卫生健康委办公厅关于印发体重管理指导原则(2024年版)的通知.国卫办医急函〔2024〕469号.2024-12-31. |
| [8] | 陈伟, 李雪, 刘小秋, 等. 《全国结核病防治规划(2024—2030年)》解读. 中国防痨杂志, 2025, 47(2):130-136. doi:10.19982/j.issn.1000-6621.20240585. |
| [9] | World Health Organization. WHO consolidated guidelines on tuberculosis: Module 6: tuberculosis and comorbidities. Geneva: World Health Organization, 2024. |
| [10] | 中华医学会糖尿病学分会, 国家基层糖尿病防治管理办公室. 国家基层糖尿病防治管理指南(2022). 中华内科杂志, 2022, 61(3): 249-262. doi:10.3760/cma.j.cn112138-20220120-000063. |
| [11] | 成君, 赵雁林. 无结核社区建设中的主动筛查策略. 中国防痨杂志, 2024, 46(6):605-612. doi:10.19982/j.issn.1000-6621.20230435. |
| [12] | 张灿有, 陈彬, 叶建君, 等. 中国重点人群肺结核患病与发病调查分析. 中国防痨杂志, 2021, 43(12): 1160-1168. doi:10.3969/j.issn.1000-6621.2021.12.006. |
| [13] | World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization, 2022. |
| [14] | Krutikov M, Faust L, Nikolayevskyy V, et al. The diagnostic performance of novel skin-based in-vivo tests for tuberculosis infection compared with purified protein derivative tuberculin skin tests and blood-based in vitro interferon-γ release assays: a systematic review and meta-analysis. Lancet Infect Dis, 2022, 22(2): 250-264. doi:10.1016/S1473-3099(21)00261-9. |
| [15] | 程玉玉. 云南省基于基本公共卫生服务模式下糖尿病患者肺结核筛查可行性分析及影响因素研究. 昆明: 昆明医科大学, 2023. doi:10.27202/d.cnki.gkmyc.2023.001177. |
| [16] | 于超, 赵长生, 张云杰. 南阳市宛城区社区肺结核可疑症状者的主动就诊情况及影响因素. 实用预防医学, 2023, 30(5): 618-620. doi:10.3969/j.issn.1006-3110.2023.05.026. |
| [17] | 梁立志. 肺结核重在预防, 警惕5大表现. 祝您健康, 2025(27): 20. |
| [18] | 竺丽梅, 卢鹏, 刘巧, 等. 社区人群结核杆菌潜伏性感染诊断方法的成本效益研究. 江苏预防医学, 2018, 29(3): 241-243. doi:10.13668/j.issn.1006-9070.2018.03.002. |
| [19] | Xia L, Xu M, Li F, et al. High accuracy of recombinant fusion protein early secretory antigenic target protein 6-culture filtrate protein 10 skin test for the detection of tuberculosis infection: a phase Ⅲ, multi-centered, double-blind, hospital-based, randomized controlled trial. Int J Infect Dis, 2023, 126: 98-103. doi:10.1016/j.ijid.2022.11.014. |
| [20] | Liu Z, Diao S, Zeng L, et al. Recombinant mycobacterium tuberculosis fusion protein for diagnosis of mycobacterium tuberculosis infection: a short-term economic evaluation. Front Public Health, 2023, 11: 1105857. doi:10.3389/fpubh.2023.1105857. |
| [21] | Diao S, Liu Z, Liu D, et al. Long-term economic evaluation of the recombinant Mycobacterium tuberculosis fusion protein (EC) test for the diagnosis of Mycobacterium tuberculosis infection. Front Pharmacol, 2023, 14: 1161526. doi:10.3389/fphar.2023.1161526. |
| [22] | 杜永成, 林淑芳, 戴志松, 等. 福建省学校结核病疫情后学生接触者结核分枝杆菌潜伏感染状况及其影响因素分析. 中国防痨杂志, 2023, 45(3): 260-264. doi:10.19982/j.issn.1000-6621.20220461. |
| [23] | 蒋骏, 李云, 姜伟, 等. 肺结核密切接触者结核分枝杆菌潜伏感染情况及影响因素分析. 结核与肺部疾病杂志, 2023, 4(4): 318-322. doi:10.19983/j.issn.2096-8493.20230065. |
| [24] | Acuña-Villaorduña C, Jones-López EC, Fregona G, et al. Intensity of exposure to pulmonary tuberculosis determines risk of tuberculosis infection and disease. Eur Respir J, 2018, 51(1): 1701578. doi:10.1183/13993003.01578-2017. |
| [25] | 钱冰, 曹红, 张欢, 等. 2017—2019年合肥市学校肺结核患者密切接触者筛查分析. 现代预防医学, 2021, 48(4): 742-744,768. |
| [26] | Xin H, Zhang H, Liu J, et al. Mycobacterium tuberculosis infection among the elderly in 20 486 rural residents aged 50-70 years in Zhongmu County, China. Clin Microbiol Infect, 2019, 25(9): 1120-1126. doi:10.1016/j.cmi.2019.01.021. |
| [27] |
Rao VG, Bhat J, Yadav R, et al. Smoking and alcohol consumption: Risk factors for pulmonary tuberculosis among the tribal community in central India. Indian J Tuberc, 2017, 64(1): 40-43. doi:10.1016/j.ijtb.2016.11.009.
pmid: 28166915 |
| [28] | Bai X, Aerts SL, Verma D, et al. Epidemiologic Evidence of and Potential Mechanisms by Which Second-Hand Smoke Causes Predisposition to Latent and Active Tuberculosis. Immune Netw, 2018, 18(3): e22. doi:10.4110/in.2018.18.e22. |
| [29] | Lin HH, Ezzati M, Murray M. Tobacco smoke, indoor air pollution and tuberculosis: a systematic review and meta-analysis. PLoS Med, 2007, 4(1): e20. doi:10.1371/journal.pmed.0040020. |
| [30] | 刘晓荣, 卓燕薇, 李彩红. 传染性肺结核患者家庭密切接触者结核隐性感染影响因素及隐性感染者预防性服药效果分析. 预防医学情报杂志, 2020, 36(10): 1335-1341, 1346. |
| [31] | 钟涛, 詹广兴, 范玉铮, 等. 深圳市南山区高危人群结核菌潜伏感染情况及影响因素. 中国热带医学, 2020, 20(8): 702-709, 716. doi:10.13604/j.cnki.46-1064/r.2020.08.03. |
| [32] | 中国防痨协会, 中国防痨协会学校与儿童结核病防治专业分会,《中国防痨杂志》编辑委员会. 重组结核杆菌融合蛋白(EC)临床应用专家共识. 中国防痨杂志, 2020, 42(8):761-768. doi:10.3969/j.issn.1000-6621.2020.08.001. |
| [33] | 崔月颖, 杨令文, 李超, 等. 新发呼吸道传染病流行期结核病防控面临的挑战与机遇. 公共卫生与预防医学, 2022, 33(6): 6-10. doi:10.3969/j.issn.1006-2483.2022.06.002. |
| [1] | . Guidelines for the diagnosis and treatment of superficial lymph node tuberculosis with integrated traditional Chinese and Western medicine [J]. Chinese Journal of Antituberculosis, 2026, 48(4): 429-447. |
| [2] | Ji Lianrong, Xue Yunlian, Jiang Xue, Yuan Shasha, Liu Guihao, Wang Xiaowan, Zou Xia, Wang Tingting, Zhou Zhanqi, Zhou Lin. Spatio-temporal distribution and clustering characteristics of comorbidities among tuberculosis inpatients in Guangdong Province from 2016 to 2024 [J]. Chinese Journal of Antituberculosis, 2026, 48(4): 448-458. |
| [3] | Liu Xi, Liu Yuze, Hua Weiyu, Li Jie, Zhang Ying, Dong Bin. Epidemiological characteristics of pulmonary tuberculosis among residents in Haidian District,Beijing from 2012 to 2022 and its correlation with population density [J]. Chinese Journal of Antituberculosis, 2026, 48(4): 459-467. |
| [4] | Miao Honghao, Zhang Jie, Pang Mengdi, Ren Yixuan, Deng Yang, Yi Junli, Fan Ruifang, Chen Shuangshuang, Chen Hao, Yu Lan, Li Jie, Li Chuanyou, Yang Xinyu. Genotypic and drug resistance of Mycobacterium tuberculosis in Beijing,2024 [J]. Chinese Journal of Antituberculosis, 2026, 48(4): 477-484. |
| [5] | Li Jing, Zhang Yangyi, Yang Jinghui, Wu Zheyuan, Li Ningdi, Yu Chenlei, Wang Lili, Shen Xuhui, Jiang Yuan, Shen Xin. Study on the characteristics of rpoB gene mutations in Mycobacterium tuberculosis and its correlation with rifampicin resistance level in Shanghai [J]. Chinese Journal of Antituberculosis, 2026, 48(4): 485-494. |
| [6] | Zhong Guowei, Zhang Shaoyi, Fan Huiling. Expression and clinical value of serum LncRNA LINC00707 and miR-382-5p in patients with pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(4): 495-503. |
| [7] | Jiang Lina, Dai Wenxi, Ju Hanfang, Meng Sukai, Wang Chunhua. Clinical value of auramine O fluorescence staining automatic microscopic scanning and recognition system for detecting tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(4): 504-509. |
| [8] | Han Yanzhuo, Lu Zhenhui, Su Ben, Zhou Rui, Chen Jiajun, Wu Xianwei, Wu Dingzhong, Zhang Shaoyan, Qiu Lei. Analysis of the clinical characteristics of post-tuberculosis bronchiectasis [J]. Chinese Journal of Antituberculosis, 2026, 48(4): 510-517. |
| [9] | Gao Xianru, Cui Wenjuan, Zhang Mengran, Yang Kefan, Hao Huiyuan, Yang Lu, Sun Wenwen. Study on the health management journey map of 15 initially treated pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2026, 48(4): 518-524. |
| [10] | Yang Jie, Dong Ning, Wei Xiaowen, Wu Yan, Dong Wenfang, Wu Yuanhao, Zhang Lin. Effects of family participatory intervention on medication adherence and lung function based on health action process approach in elderly patients with pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(4): 525-533. |
| [11] | Du Fangfang, Cao Xuefang, Wang Jin, Jin Qi, Liu Jianjun, Gao Lei, Cheng Shiming. Analysis of current developing situation of group standards of Chinese Antituberculosis Association [J]. Chinese Journal of Antituberculosis, 2026, 48(4): 534-540. |
| [12] | Zhou Wensi, Guo Meng, Chen Qingbo, Wang Quan, Li Wei. Comparative analysis of published literature in Chinese and English on multidrug-resistant tuberculosis from 2004 to 2025 [J]. Chinese Journal of Antituberculosis, 2026, 48(4): 541-549. |
| [13] | Qiu Yuxian, Huang Fang, Yang Xiaoyi, Yang Feng, Lu Hua, Zhang Tianyi, Zhang Yang, Yao Rong, Li Yuanyuan. Research progress in digital twin technology for tuberculosis patient management [J]. Chinese Journal of Antituberculosis, 2026, 48(4): 550-555. |
| [14] | Shu Wei, Liu Yuhong. Interpretation of research and innovation part of the WHO Global Tuberculosis Report 2025 [J]. Chinese Journal of Antituberculosis, 2026, 48(3): 307-312. |
| [15] | Wang Jing, Jing Wei, Li Weiwen, Zhu Qingdong, Pang Yu, Chu Naihui, Nie Wenjuan. Clinical cohort analysis of the efficacy and safety of extended-course bedaquiline in patients with multidrug-resistant/rifampicin-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(3): 313-319. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
京公网安备11010202007215号
Total visitors: Visitors of today: Now online:
This work is licensed under Creative Commons Attribution 3.0 License.